

Updated 8/21/2024

Blood Banking/Transfusion Medicine Major Category Code Headings												
1	Clinical Practice											10004
2	Histocompatibility and Tissue Banking											10500
3	RBCs and RBC Components											10800
4	Apheresis											11400
5	Hazards of Transfusion: Specific Adverse Events											11800
6	Plasma Components and Derivatives											12200
7	Infectious Hazards of Transfusion											12400
8	Blood Donors and Blood Collection											13000
9												13200
10	Surgery Patients											13500
11	Biovigilance											13900
12	Platelet and Platelet Components											14000

										Cat Code
Blood Banking/Transfusion Medicine										10000
1 Clinical Practice										10004
A		Autoimmune Hemolytic Anemia								10008
		1	Classification, Epidemiology, and Causes							10012
		2	Warm autoimmune hemolytic anemia							10016
			a	Pathophysiology						10020
			b	Autoantibodies and Specificity						10024
			c	Clinical Features						10028
			d	Laboratory Features						10032
			e	Treatment						10036
		3	Cold Hemagglutinin Disease							10040
			a	Pathophysiology						10044
			b	Autoantibodies and Specificity						10048
			c	Clinical Features						10052
			d	Laboratory Features						10056
			e	Treatment						10060
		4	Paroxysmal Cold Hemoglobinuria							10064
			a	Pathophysiology						10068
			b	Autoantibodies and Specificity						10072
			c	Clinical Features						10076
			d	Laboratory Features						10080
			e	Treatment						10084
		5	Drug-Induced Immune Hemolytic Anemia							10088
			a	Drug Adsorption Mechanism						10092
			b	Drug-Dependent Antibody Mechanism						10096
			c	Autoimmune Induction Mechanism						10100
B		Paroxysmal Nocturnal Hemoglobinuria								10104
		1	Clinical Picture and Course							10108
		2	Causes and Pathogenesis							10112
		3	Laboratory Features							10116
		4	Treatment							10120
		5	Transfusions							10124
C		Anemia in Oncology Patients								10128
		1	Causes							10132
		2	Clinical Features							10136
		3	Management							10140
			a	Growth Factors						10144
			b	Transfusion Therapy						10148
D		Immune Thrombocytopenia								10152
		1	General Tests to Investigate Thrombocytopenia							10156
		2	Platelet Antibody Assays (non-HIT)							10160
		3	Tests for Heparin-Induced Thrombocytopenia							10164
		4	Platelet genotyping							10168
		5	Idiopathic (Immune) Thrombocytopenic Purpura							10172
			a	Pathogenesis						10176
			b	Clinical Features						10180
			c	Laboratory Features						10184
			d	Treatment						10188
			e	Immune Thrombocytopenic Purpura in Pregnancy						10192

					f	Acute Immune Thrombocytopenic Purpura of Childhood	10196	
					g	Chronic Immune Thrombocytopenic Purpura of Childhood	10200	
					h	Secondary Immune Thrombocytopenic Purpura	10204	
			6			Drug-Induced Immune Thrombocytopenia	10208	
					a	Heparin-Induced Thrombocytopenia	10212	
						i	Pathogenesis	10216
						ii	Treatment and Management	10220
					b	Typical Drug-Induced Immune Thrombocytopenia	10224	
					c	Atypical Drug-Induced Thrombocytopenic Purpura	10228	
					d	Drug-Induced Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome	10232	
			7			Alloimmune Thrombocytopenia	10236	
					a	Platelet Alloantigens , Immunogenetics and Frequency of Alloimmune Thrombocytopenia	10240	
					b	Neonatal Alloimmune Thrombocytopenia	10244	
						i	Pathophysiology and Clinical Features	10248
						ii	Neonatal Treatment	10252
						iii	Prenatal Management	10256
					c	Posttransfusion Purpura	10260	
						i	Pathophysiology and Clinical Features	10264
						ii	Treatment	10268
					d	Passive Alloimmune Thrombocytopenia	10272	
					e	Transplantation-Associated Alloimmune Thrombocytopenia	10276	
						i	Hematopoietic Transplantation	10280
						ii	Solid organ Transplantation	10284
					f	Platelet Transfusion Refractoriness – Causes, Mechanisms and Management	10288	
		E				Bleeding From Congenital and Acquired Coagulation Defects and Antithrombotic Therapy	10292	
			1			Liver Disease	10296	
					a	Pathophysiology	10300	
					b	Laboratory Features	10304	
					c	Management of Bleeding	10308	
			2			Vitamin K Deficiency	10312	
					a	Role of Vitamin K in Hemostasis	10316	
					b	Hemorrhagic Disease of the Newborn	10320	
					c	Other Causes of Vitamin K Deficiency	10324	
					d	Treatment	10328	
			3			Disseminated Intravascular Coagulation	10332	
					a	Pathophysiology	10336	
					b	Clinical Features	10340	
					c	Laboratory Features	10344	
					d	Treatment	10348	
			4			Coagulation Factor Inhibitors	10352	
					a	Factor VIII Inhibitors	10356	

			b	Lupus Anticoagulants				10360
			c	Acquired von Willebrand Syndrome				10364
			d	Factor V Inhibitors				10368
			e	Acquired Factor X Deficiency				10372
			f	Other Coagulation Inhibitors				10376
		5		Acquired Platelet Function Disorders				10380
			a	Drug-Induced Platelet Dysfunction				10384
			b	Uremia				10388
			c	Cardiopulmonary Bypass				10392
		6		Antithrombotic Therapy				10396
			a	Warfarin				10400
			b	Heparin				10404
			c	Low Molecular Weight Heparins				10408
			d	Factor Xa Inhibitors				10412
			e	Direct Thrombin Inhibitors				10416
			f	Fibrinolytic Agents				10420
		7		Congenital Coagulopathies/Thrombophilias				10421
			a	Von Willebrand Disease				10422
			b	Factor Deficiencies, At III, Protein C, Protein S Deficiencies				10423
	F			Granulocyte Transfusion (Primarily Donor Issues)				10424
		1		Indications and Patient Selection				10428
		2		Donor Selection and Criteria				10432
		3		Donor Stimulation – Corticosteroids and G-CSF				10436
		4		Product Collection				10440
		5		Product Storage and Transport				10444
		6		Product Selection – Special Needs				10448
		7		Infusion and Monitoring				10452
		8		Adverse Events (Donor and Recipient)				10456
		9		Clinical Outcomes				10460
	G			Transfusion Risks and Reactions in Oncology				10464
		1		Infectious				10468
		2		Graft-Versus-Host Disease				10472
		3		Alloantibodies				10476
		4		Iron Overload				10480
2				Histocompatibility and Tissue Banking				10500
	A			HLA Antigens and Alleles				10504
		1		Major Histocompatibility Complex				10508
		2		Class I and II Antigens and Their Function				10512
		3		Polymorphism of HLA System and Nomenclature				10516
		4		Identification of HLA Antigens, Antibodies and Alleles				10520
			a	Serologic Methods				10524
			b	Cellular Methods				10528
			c	Nucleic Acid-Based Methods				10532
			d	Crossmatching				10534
		5		Genotypes, Phenotypes and Haplotypes				10536
		6		Medical and Biological Significance of HLA				10540
			a	Transplantation				10544
				i Hematopoietic Progenitor Cell				10548
				ii Solid Organ				10552
			b	Disease Association				10556
	B			Tissue banking				10560
		1		Human Allograft Applications				10564

			2	Tissue Donation						10568
				a	Living Donors					10572
				b	Deceased Donors					10576
				c	Referral for Donation					10580
			3	Organization of Tissue Banking in the United States						10584
			4	Public Attitudes Regarding Organ and Tissue Donation						10588
			5	Tissue Transplant-Transmissible Diseases						10592
			6	Tissue Donor Suitability and Tissue Transplant Risk Reduction						10596
				a	Donor History Screening					10600
				b	Donor Physical Assessment					10604
				c	Tissue Recovery Methods					10608
				d	Infectious Disease Testing					10612
				e	Tissue Sterilization					10616
			7	General Principles of Tissue Preservation and Clinical Use						10620
				a	Bone					10624
				b	Cartilage, Meniscus, Tendon, Ligament and Dura Mater					10628
				c	Skin					10632
				d	Ocular Tissue					10636
				e	Cardiovascular Tissue					10640
				f	Peripheral Nerve					10644
				g	Parathyroid					10648
				h	Reproductive Tissue					10652
				i	Semen					10656
				ii	Oocytes and Embryos					10660
				iii	Extraembryonic					10664
			8	Transfusion Service Support of Tissue Transplantation						10668
			9	Tissue Banking and Transplantation Oversight						10672
		C	Adoptive Immunotherapy							10676
			1	Immunotherapy Targets for Cancer						10680
			2	T-Cell Immunotherapy Targets for Infections						10684
			3	Types of Adoptive Immunotherapy						10688
				a	Non-specific T Cells					10692
				b	Antigen-Specific T Cell Therapies					10696
				c	Genetically-Modified T Cells					10700
			4	Approaches to Improving Cellular Immunotherapy						10704
			5	Adoptive Immunotherapy regulatory Issues						10708
		D	Gene Therapy in Transfusion Medicine							10712
			1	Targeted Genes						10716
			2	Vector Design						10720
			3	Viral Vectors						10724
			4	Adeno-Associated Virus						10728
			5	Adenoviral vectors						10732
			6	Non-Viral Gene Therapy						10736
			7	Clinical Protocols and Trials						10740
		E	Tissue Engineering and Regenerative Medicine							10744
			1	Overview						10748
			2	Skin						10752
			3	Blood Vessel						10756
			4	Bone						10760

		5	Cartilage								10764
		6	Urology								10768
		7	Cardiac								10772
		8	Corneal								10776
3	RBCs and RBC Components										10800
	A	Red Cell Production and Kinetics									10804
		1	Erythropoietin								10808
			a	Regulation of Production							10812
			b	Interaction with and Effects on Erythroid Progenitor Cells							10816
		2	Nutritional Requirements for Erythropoiesis								10820
		3	Influence of Pathologic States on Erythropoiesis								10824
	B	Oxygen Delivery and Use of Red Cells and Red Cell Substitutes for Oxygen Delivery									10828
		1	Regulation of Systemic Oxygen Delivery								10832
		2	Regulation of Regional Oxygen Delivery								10836
		3	Regulation of Oxygen Delivery in the Microcirculation								10840
			a	Red Cell Transfusion and the Microcirculation							10844
			b	Effect of Red Cell Storage Changes on the Microcirculation (N Oxide)							10848
		4	Oxygen carrying Red Cell Substitutes								10852
			a	Hemoglobin-Based							10856
			b	Perfluorocarbon-Based							10860
	C	Red Cell Metabolism and Preservation									10864
		1	Metabolism								10868
			a	Glucose							10872
			b	Alternative Substrates							10876
			c	Regulation of Energy Metabolism							10880
			d	Synthetic Processes							10884
			e	Membrane Metabolism							10888
		2	Red Cell Preservation in Transfusion Medicine								10892
			a	General Principles							10896
			b	Collection and Separation Procedures							10900
			c	Anticoagulant-Nutrient Solutions							10904
			d	Additive Solutions							10908
			e	Additional Factors Influencing RBC Quality							10912
			f	Functionality							10916
			g	Rejuvenation							10920
			h	Frozen Storage							10924
			i	Validation of RBC Storage Systems							10928
	D	Red Cell Immunology and Compatibility Testing									10932
		1	Red Cell Immunology								10936
			a	Immune Response – Components and Characteristics							10940
			b	Blood Group Antibodies - Physical Properties and Characteristics							10944
			c	Red Cell Antigen-Antibody Interactions							10948
				i	Direct Agglutination						10952
				ii	Hemolysis						10956
				iii	Antiglobulin test (DAT)						10960
		2	Compatibility Testing								10964
			a	Donor Testing							10968

					b	Patient testing				10972
						i	Sample Collection			10976
						ii	ABO Typing			10980
						iii	Rh Typing			10984
						iv	Tests for Unexpected Antibodies			10988
						v	Reagents Red Cells for Antibody Detection			10992
						vi	Automated Pretransfusion testing			10996
						vii	Additional Techniques			11000
						viii	Molecular Techniques			11002
					c	Principles of Antibody Identification				11004
					d	Donor-Recipient Testing				11008
						i	Prior Records Check			11012
						ii	Selection of Blood for Transfusion			11016
						iii	Serologic Crossmatch			11020
						iv	Electronic Crossmatch			11024
						v	Labeling			11028
						vi	Issue			11032
						vii	Emergency Release			11036
						viii	Bedside Check			11040
						ix	Hemovigilance			11044
		E				Carbohydrate Blood Groups and Blood Group Systems				11048
			1			ABH Antigens				11052
					a	Biochemistry				11056
					b	Antigenic variants				11060
					c	Secretion				11064
					d	Se and H genes				11068
					e	H-Deficient Phenotypes and Genotypes				11072
					f	Medical Implications of the ABH and Secretor Systems				11076
						i	ABO-Incompatible Solid Organ Transplantation			11080
						ii	ABO-Incompatible Hematopoietic Progenitor Cell Transplantation			11084
			2			Lewis System				11088
			3			Ii System				11092
			4			P System				11096
		F				Rh and LW Blood Group Systems				11100
			1			Rh Blood Group System - General Information and Nomenclature				11104
			2			Rh Genes and Their Expressed Proteins				11108
			3			Molecular Basis for Rh Antigen Expression				11112
					a	D Antigen				11116
					b	C/c and E/e Antigens				11120
					c	RH Genotyping				11124
			4			Rh-membrane Complex				11128
			5			Rh Function				11132
			6			Immune Response to Rh				11136
					a	Medical Aspects				11140
					b	Serologic Aspects				11144
					c	Molecular Aspects				11148
			7			LW Blood Group System				11152

			a	General information					11156	
			b	Genes and Their Expressed Proteins					11160	
			c	Molecular Basis for Antigen Expression					11164	
			d	LW Function					11168	
		G	Other Protein Blood Group Systems							11172
			1	Kell and Kx Blood					11176	
				a	Structure, Function, and Interaction of the Kell and XK Proteins				11180	
				b	Kell - Transfusion Medicine Aspects				11184	
					i	Transfusions			11188	
					ii	Hemolytic Disease of the Fetus and Newborn			11192	
				c	Kell Variants				11196	
			2	Duffy					11200	
				a	Structure and Function of the Duffy Protein				11204	
				b	Duffy - Transfusion Medicine Aspects				11208	
					i	Transfusions			11212	
					ii	Hemolytic Disease of the Fetus and Newborn			11216	
			3	Kidd					11220	
				a	Structure and Function of the Kidd Protein				11224	
				b	Kidd - Transfusion Medicine Aspects				11228	
					i	Transfusions			11232	
					ii	Hemolytic Disease of the Fetus and Newborn			11236	
			4	MNS					11240	
				a	Structure and Function of Glycophorins A and B				11244	
				b	MNS - Transfusion Medicine Aspects				11248	
			5	Diego					11252	
			6	Gerbich					11256	
			7	Colton and GIL					11260	
			8	Lutheran					11264	
			9	Indian, Xg, and Scianna					11268	
			10	Chido/Rodgers					11272	
			11	Knops					11276	
			12	Cartwright, Dombrock, Cromer and JMH					11280	
			13	OK and RAPH					11284	
		H	Anemia and Red Blood Cell Transfusion							11288
			1	Physiologic Adaptations to Blood Loss and Anemia						11292
				a	Oxygen Transport Principles and Mechanisms				11296	
				b	Adaptive Mechanisms in Anemia				11300	
				c	Microcirculatory Effects of Anemia and Red Cell Transfusion				11304	
				d	Pathophysiologic Processes and Anemia – Interactions				11308	
			2	Clinical Outcomes of Anemia and Red Cell Transfusion						11312
				a	Risks of Anemia				11316	
				b	Efficacy of Transfusion				11320	
					i	Adults			11324	
					ii	Children			11328	
			3	Transfusion Guidelines						11332

			4	Red Cell Transfusions - Decision Making	11336
				a Bleeding Patient	11340
				b Surgical Patient	11344
				c Chronic Anemia	11348
				d Transfusion Threshold	11352
				e Dose and Administration	11356
4	Apheresis				11400
	A	Apheresis: Principles and Technology of Hemapheresis			11404
		1	General Information and Principles		11408
		2	Current Devices and Technology		11412
		3	Donor Apheresis		11416
			a	Donor Care	11420
			b	Specific Products and Procedures	11424
			c	Adverse Effects on Donors and Recipients	11428
		4	Therapeutic Apheresis		11432
			a	Procedural and Technical Aspects	11436
				i Substances Removed	11440
				ii Volume Removed	11444
				iii Replacement Fluids (Technical and Composition Details)	11448
				iv Schedule of Procedures (Timing, Number, Location)	11452
				v Equipment	11456
				vi Vascular access	11460
				vii Anticoagulant	11464
				viii Oversight	11468
				ix Adverse Effects	11472
	B	Therapeutic Plasma Exchange			11476
		1	General Principles		11480
			a	Mathematic Principles	11484
			b	Regulation of IgG Metabolism	11488
			c	Replacement Fluids (Clinical Aspects)	11492
			d	Selective Extraction of Plasma Components	11496
			e	Indication and Treatment Intensity Categories	11500
		2	Neurologic Disorders		11504
			a	Guillain-Barré Syndrome	11508
			b	Chronic Inflammatory Demyelinating Polyneuropathy	11512
			c	Peripheral neuropathy and Monoclonal Gammopathy	11516
			d	Myasthenia Gravis	11520
			e	Lambert-Eaton Myasthenic Syndrome	11524
			f	Neuromyotonia and Limbic Encephalitis	11528
			g	Stiff-Person Syndrome	11532
			h	Paraneoplastic Neurologic Syndromes	11536
			i	Nonneoplastic Disorders with Central nervous System Antibodies	11540
			j	Multiple Sclerosis	11544
		3	Hematologic and Oncologic Disorders		11548
			a	Monoclonal Proteins	11552
			b	Blood Cell Alloantibodies	11556
			c	Thrombotic Thrombocytopenic Purpura	11560

				d	Hemolytic Uremic Syndrome	11564
				e	Posttransfusion Purpura	11568
				f	Idiopathic (Immune) Thrombocytopenic Purpura	11572
				g	Autoimmune Hemolytic Anemia	11576
				h	Pure Red Cell Aplasia and Aplastic Anemia	11580
				i	Coagulation Factor Inhibitors	11584
			4		Rheumatic and Other Immunologic Disorders	11588
				a	Cryoglobulinemia	11592
				b	Rheumatoid Arthritis	11596
				c	Systemic Lupus Erythematosus	11600
				d	Systemic Vasculitis Polymyositis and Dermatomyositis	11604
				e	Goodpasture Syndrome	11608
				f	Rapidly Progressive Glomerulonephritis – Other	11612
				g	Solid Organ Transplantation	11616
					i Rejection	11620
					ii Disease Recurrence	11624
			5		Toxic and Metabolic Disorders	11628
				a	Hypercholesterolemia	11632
				b	Refsum's Disease	11636
				c	Drug Overdose and Poisoning	11640
				d	Acute Liver Failure	11644
			C		Specialized Therapeutic Hemapheresis and Phlebotomy	11648
			1		Red Cell Exchange	11652
				a	Principles and Techniques	11656
				b	Sickle Cell Disease	11660
				c	Acute and/or Emergent Complications – Indications and Management	11664
				d	Chronic Conditions or Preventive Strategies – Indications and Management	11668
				e	Malaria	11672
				f.	Babesiosis	11676
			2		Erythrocytapheresis and Therapeutic Phlebotomy	11680
				a	Polycythemia Vera	11684
				b	Secondary Erythrocytosis	11688
				c	Hereditary Hemochromatosis	11692
			3		Therapeutic Platelet Apheresis	11696
				a	Primary Thrombocytosis	11700
				b	Secondary Thrombocytosis	11704
			4		Therapeutic White Cell Apheresis	11708
				a	Hyperleukocytosis	11712
				b	Inflammatory Bowel Disease	11716
			5		Extracorporeal Photochemotherapy	11720
				a	Techniques and Mechanisms	11724
				b	Cutaneous T-Cell Lymphoma	11728
				c	Cardiac Allograft Rejection	11732
				d	Graft-Versus-Host Disease	11736
			6		Selective Extraction of Low-Density Lipoproteins	11740
				a	Principles, Indications, and Techniques	11744
5					Hazards of Transfusion: Specific Adverse Events	11800

		1	Pathophysiology						12004
		2	Incidence						12008
		3	Risk Factors - General						12012
		4	Fetuses and Neonates						12016
		5	Patient Populations At Risk						12020
			a	Congenital Immunodeficiency Syndromes					12024
			b	Malignancies					12028
			c	Hematopoietic Progenitor Cell Transplants					12032
			d	Solid Organ Transplants					12036
		6	Immunocompetent Patients – Risk Factors						12040
		7	Clinical Presentation and Diagnosis						12044
		8	Treatment						12048
		9	Prevention						12052
	D	Transfusion-Induced Iron Overload							12056
		1	Pathophysiology						12060
		2	Iron Burden of Transfusions						12064
		3	Clinical Features						12068
		4	Measurement of Iron Burden						12072
		5	Management						12076
			a	Goals					12080
			b	Chelation Therapy					12084
	E	Transfusion-Related Acute Lung Injury							12088
		1	Incidence and Epidemiology						12092
		2	Clinical Features						12096
		3	Pathophysiology						12100
			a	Acute Lung Injury - Features					12104
			b	Causes					12108
			c	Mechanisms of Lung Damage					12112
			d	Multiple Hit/Threshold Theory					12116
		4	Diagnosis and Differential Diagnosis						12120
			a	Clinical, Physiologic, Radiologic, and Laboratory Features					12124
			b	Consensus Definition					12128
		5	Treatment and Management						12132
		6	Donor Investigation						12136
		7	Prevention						12140
	F	Posttransfusion Purpura							12160
		1	Pathophysiology and Clinical Features						12164
		2	Treatment						12168
	G	Transfusion-Associated Dyspnea							12180
6	Plasma Components and Derivatives								12200
	A	Plasma Composition							12204
		1	General Features and Factors Influencing Plasma Composition						12208
		2	Albumin						12212
		3	Immunoglobulins						12216
		4	Alpha-1-Antitrypsin						12220
		5	C1 Inhibitor						12224
		6	Von Willebrand Factor Cleaving Protease						12228
		7	Coagulation Factors, Coagulation Factor Inhibitors, and von Willebrand Factor e.g. description, half-life						12232
	B	Preparation of Plasma Derivatives							12236
		1	Plasma Procurement						12240

			2	Plasma Manufacture					12244
			3	Pathogen Inactivation/Removal					12248
			4	Plasma Products – Indications and Clinical Use					12252
				a. Prothrombin Complex Concentrate (PCC)					12253
			5	Adverse Effects					12256
			6	Industry Safety Programs					12260
			7	Recombinant DNA Technology and Manufacturing					12264
				a. Recombinant Factor VIIa					12265
		C		Plasma Transfusion and Use of Albumin and Rh Immune Globulin					12268
			1	Fresh Frozen, Frozen, Cryo-Poor, Thawed, and Stored Plasma					12272
				a	Manufacture and Features				12276
				b	Clinical Use, Indications and Guidelines for Use				12280
					i	Surgery			12284
					ii	Massive Transfusion, Trauma, and Disseminated Intravascular Coagulation			12288
					iii	Intensive care			12292
					iv	Liver Disease			12296
					v	Warfarin Reversal			12300
					vi	Therapeutic Apheresis			12304
				c	Dosing				12308
				d	Risks and Adverse Effects				12312
				e	Pathogen-Inactivated Plasma				12316
			2	Cryoprecipitate					12320
				a	Manufacture and Features				12324
				b	Clinical Use, Indications and Guidelines for Use				12328
				c	Risks and Adverse Effects				12332
			3	Albumin					12336
				a	Manufacture and Features				12340
				b	Clinical Use, Indications and Guidelines for Use				12344
				c	Risks and Adverse Effects				12348
			4	Rh Immune Globulin					12350
				a	Manufacture and Features				12354
				b	Clinical Use, Indications and Guidelines for Use				12358
				c	Risks and Adverse Effects				12362
			5	IVIG					12370
			6	Other Plasma Derivatives, e.g. CMV, IG, HBV,IG, ISG, Rabies IG					12380
				a	Alpha-1-Antitrypsin				12385
				b	C1 Inhibitor				12390
				c	Fibrinogen concentrates				12395
			7	Infectious Hazards of Transfusion					12400
		A		Transfusion-Transmitted Hepatitis					12404
			1	Incidence					12408
			2	Hepatitis B Virus					12412
				a	Epidemiology				12416

				b	Transmission				12420
				c	Clinical Features				12424
					i	Acute Infection			12428
					ii	Chronic Infection			12432
				d	Serologic and Molecular Markers of Infection				12436
				e	Donor Testing and Counseling				12440
				f	Prevention				12444
				g	Treatment				12448
			3		Hepatitis C Virus				12452
				a	Epidemiology				12456
				b	Transmission				12460
				c	Clinical Features				12464
					i	Acute Infection			12468
					ii	Chronic Infection			12472
				d	Donor Testing and Counseling				12476
				e	Prevention				12480
				f	Treatment				12484
			4		Hepatitis A Virus				12488
				a	Epidemiology				12492
				b	Transmission				12496
				c	Clinical Features				12500
				d	Donor Testing and Counseling				12504
				e	Prevention				12508
				f	Treatment				12512
			5		Hepatitis D and Hepatitis E Virus				12516
				a	Epidemiology				12520
				b	Diagnosis				12524
				c	Transmission				12528
				d	Clinical Features				12532
				e	Prevention				12536
			6		Non-A, Non-B, Non-C Hepatitis				12540
	B				Retroviruses				12544
			1		Overview				12548
			2		Human Immunodeficiency Virus				12552
				a	General Information and Epidemiology				12556
				b	Incidence and Prevalence Among Blood Donors				12560
				c	Window Period and Risk of Transmission				12564
				d	Donor Testing and Counseling				12568
				e	Clinical Features				12572
				f	Prevention				12576
				g	Treatment				12580
			3		Human T-Cell Lymphotropic Viruses (HTLV)				12584
				a	General Information and Epidemiology				12588
				b	Incidence and Prevalence Among Blood Donors				12592
				c	Window Period and Risk of Transmission				12596
				d	Donor Testing and Counseling				12600
				e	Clinical Features				12604
				f	Prevention				12608
				g	Treatment				12612
	C				Cytomegalovirus (CMV)				12616

		1	General Information and Epidemiology	12620
		2	Incidence and Prevalence Among Blood Donors	12624
		3	Window Period and Risk of Transmission	12628
		4	Donor Testing and Counseling	12632
		5	Clinical Features	12636
		6	Prevention	12640
		7	Treatment	12644
		8	Other herpesviruses	12646
	D		Other Viruses	12648
		1	Parvovirus B19	12652
			a General Information and Epidemiology	12656
			b Transmission	12660
			c Clinical Features	12664
		2	West Nile Virus	12668
			a General Information and Epidemiology	12672
			b Transmission	12676
			c Donor Testing and Counseling	12680
			d Clinical Features	12684
			e Prevention	12688
			f Zika, Dengue and Chikungunya	12690
	E		Transfusion Transmission of Parasites	12692
		1	Chagas' Disease	12696
			a General Information and Epidemiology	12700
			b Transmission	12704
			c Donor Testing and Counseling	12708
			d Clinical Features	12712
			e Prevention	12716
		2	Malaria	12720
			a General Information and Epidemiology	12724
			b Transmission	12728
			c Donor Testing and Counseling	12732
			d Clinical Features	12736
			e Prevention	12740
		3	Babesiosis	12744
			a General Information and Epidemiology	12748
			b Transmission	12752
			c Donor Testing and Counseling	12756
			d Clinical Features	12760
			e Prevention	12764
			f Treatment	12766
		4	Leishmaniasis	12768
			a General Information and Epidemiology	12772
			b Transmission	12776
			c Donor Testing and Counseling	12780
			d Clinical Features	12784
			e Prevention	12788
	F		Bacterial Contamination of Blood Products	12792
		1	Red Blood Cells – Overview and Epidemiology	12796
		2	Allogeneic RBCs – Agents and Incidence	12800
		3	Autologous RBCs – Agents and Incidence	12804
		4	Plasma, Cryoprecipitate and Derivatives - Agents and Incidence	12808

			5	Platelets							12812
				a	Source of Contamination						12816
				b	Agents and Incidence						12820
				c	Clinical Features						12824
				d	Treatment						12828
				e	Prevention						12832
			6	Strategies to Reduce the Risk of Posttransfusion Sepsis							12836
				a	Donor Screening						12840
				b	Skin Preparation						12844
				c	Diversion						12848
				d	Apheresis Versus Whole Blood-Derived Platelets					12852	
				e	Storage Time and Temperature					12856	
				f	Bacterial Detection					12860	
				g	Bacterial Elimination					12864	
			7	Syphilis							12868
			8	Lyme Disease							12872
	G	Prion Diseases							12876		
			1	General Information and Epidemiology							12880
			2	Transmission							12884
			3	Clinical Features							12888
			4	Risk Management – Donor Selection							12892
			5	Blood Component Processing							12896
			6	Plasma Derivative manufacture							12900
			7	Cellular, Tissue, and Organ Transplantation							12904
	H	Pathogen Inactivation							12908		
			1	Overview and description							12912
			2	Plasma							12916
				a	Solvent/Detergent Treatment						12920
				b	Methylene Blue Light Treatment						12924
				c	Psoralen Ultraviolet Light Treatment						12928
				d	Riboflavin Light Treatment						12932
			3	Platelet							12936
				a	Psoralen Ultraviolet Light Treatment						12940
				b	Riboflavin Light Treatment						12944
				c	Thionine Light Treatment						12948
			4	Red Cell							12952
				a	Alkylating Agents						12956
				b	Photosensitizers						12960
				c	Riboflavin Light Treatment						12964
			5	Emerging Technologies							12968
8	Blood Donors and Blood Collection										13000
	A	Recruitment and Screening of Donors and the Collection, Processing and testing of Blood									13004
			1	Organization of Blood Services							13008
				a	United States						13012
				b	Outside United States						13016
			2	Blood Donor Recruitment							13020
			3	Collection Process							13024
				a	Donor Evaluation						13028
					i	Consent					13032

					ii	History and Physical Examination	13036
					iii	Laboratory Testing	13040
					iv	Deferral Criteria	13044
				b	Blood Collection		13048
					i	Whole Blood	13052
					ii	Component Separation	13056
					iii	Leukocyte Reduction	13060
					iv	Automated Collection	13064
				c	Blood Component Testing		13068
					i	ABO/Rh	13072
					ii	Antibody Screening	13076
					iii	Infectious Disease	13080
				d	Distribution		13084
				e	Source Plasma		13088
			4	Blood Donor Adverse Events			13092
				a	Donor Reactions		13096
					i	Categories	13100
					ii	Incidence	13104
					iii	Clinical Features	13108
					iv	Risk Factors	13112
					v	Treatment	13116
					vi	Prevention	13120
				b	Phlebotomy-Related		13124
					i	Categories	13128
					ii	Incidence	13132
					iii	Clinical Features	13136
					iv	Risk Factors	13140
					v	Treatment	13144
					vi	Prevention	13148
				c	Long-Term Effects of Donation		13152
					i	Iron	13156
					ii	Platelets	13160
					iii	Plasma Proteins	13164
9	Management, Quality, Legal, & Regulatory Issues in Transfusion Med. & Transplantation						13200
	A	Current Legal Issues					13204
		1	Blood Transfusion Injury Claims				13208
			a	Blood Shield Laws			13212
			b	Negligence			13216
			c	Standard of Care			13220
			d	Causation			13224
			e	Informed Consent			13228
		2	Donor Injury				13232
		3	Cord Blood				13236
		4	Tissue Banking				13240
		5	HIPAA Privacy Rule				13244
	B	Current Good Manufacturing Practice					13248
		1	General Overview				13252
		2	Licensing Products and Establishments				13256
		3	Recalls and FDA Enforcement Activities				13260
		4	Safety Initiatives				13264
		5	Enforcement Options				13268

			6	Rationale							13272	
				a	Standard Operating Procedures						13276	
				b	Record Keeping						13280	
				c	Personnel and Training						13284	
				d	Calibration						13288	
				e	Validation						13292	
				f	Labeling						13296	
				g	Error Management						13300	
				h	Quality Control Unit and Internal Audits						13304	
				i	Facilities and Equipment						13308	
				j	Process and Production Controls						13312	
			7	Information Management							13316	
			8	Common Violations							13320	
		C		Transplant Organizations and Networks in the Regulation of Cellular and Tissue Therapy Programs								13324
			1	Hematopoietic Progenitor Cells								13328
				a	Sources						13332	
				b	Indications						13336	
				c	HLA Matching						13340	
				d	Donor Registries and Networks						13344	
				e	Outcomes Registries, Professional Associations and Networks						13348	
				f	Accrediting Organizations						13352	
			2	Other Cellular Therapies								13356
				a	Organizational Aspects						13360	
				b	Accreditation and Regulation						13364	
			3	Tissue Banks								13368
				a	Organizational Aspects						13372	
				b	Accreditation and Regulation						13376	
		D		Hospital Transfusion Services, Transfusion Committee and Quality Assurance								13380
			1	Role of the Medical Director								13384
				a	Administrative						13388	
				b	Clinical						13392	
				c	Education						13396	
			2	Quality Assurance								13400
				a	Process Control						13404	
				b	Error Management						13408	
				c	Improving Transfusion Practice						13412	
			3	Regulatory and Accreditation Requirements								13416
				a	Food and Drug Administration						13420	
				b	AABB						13424	
				c	Joint Commission						13428	
				d	College of American Pathologists						13432	
			4	Transfusion Committee								13436
				a	Membership						13440	
				b	Functions						13444	
				c	Oversight of Transfusion Policies, Procedures, and Guidelines						13448	
				d	Education						13452	
		E		Other Administrative Issues								13455
10				Surgery Patients								13500

	A	Alternatives to Transfusion: Perioperative Blood Management	13504
		1 Preoperative	13508
		a Autologous Blood Donation	13512
		b Anemia optimization	13516
		i Iron	13520
		ii Erythropoietin	13524
		2 Intraoperative/Postoperative	13528
		a Acute Normovolemic hemodilution	13532
		b Intraoperative autologous blood recovery and reinfusion (cell salvage)	13536
		c Postoperative autologous blood recovery and reinfusion	13540
	B	Hemostasis for Surgery/Invasive Procedures	13544
		1 Preprocedure Blood Components	13548
		a Common Laboratory tests of Hemostasis and Their Relationship With Procedure-related Bleeding	13552
		b Procedure-Related Bleeding	13556
		i Central Venous Catheter	13560
		ii Liver Biopsy	13564
		iii Thoracentesis and Paracentesis	13568
		iv Gastrointestinal Endoscopy and Biopsy	13572
		v Procedures on Upper Airway, Bronchoscopy, and Transbronchial Lung Biopsy	13576
		vi Renal Biopsy	13580
		vii Epidural Anesthesia, Lumbar Puncture, and Neurosurgical Procedures	13584
		viii Angiography	13588
		2 Treatment of Bleeding	13592
		a Local	13596
		i Physical – Sutures, Electrocautery, Compression, Direct Packing, etc	13600
		ii Topical Agents	13604
		iii Topical Sealants	13608
		iv Topical Thrombin	13612
		v Topical Antifibrinolytics	13616
		b Generalized	13620
		i Skin and Membrane	13624
		ii Purpura and Soft Tissue	13628
		iii Small Vessel Bleeding During Surgery	13632
		iv DDAVP	13634
	C	Transfusion Therapy for Trauma and Burn Patients	13636
		1 Shock	13640
		a General Information and Definition	13644
		b Hemorrhagic Shock and Classification	13648
		i Acidosis	13652
		ii Hypothermia	13656
		iii Coagulopathy	13660
		c Trauma Patient	13664
		i Initial Resuscitation	13668
		aa Damage Control	13672
		ab Blood Component Therapy	13676

									ac	Hemostatic Agents	13680	
									ad	Pharmacologic Agents	13684	
								ii	Intraoperative		13688	
									aa	Damage Control	13692	
									ab	Temperature	13696	
									ac	Blood Component Therapy	13700	
									ad	Autotransfusion	13704	
									ae	Solid Organ Injury	13708	
									af	Hemostatic Agents	13712	
									ag	Pharmacologic Agents	13716	
								iii	Recovery Phase		13720	
									aa	Blood Component Therapy	13724	
								iv	Massive Transfusion		13728	
									aa	Definition	13732	
									ab	Blood Component Therapy	13736	
									ac	Complications	13740	
								d	Burn Patient		13744	
									i	Initial Resuscitation		13748
									aa	Fluid Therapy		13752
										1	Colloid	13756
										2	Crystalloid	13760
									ab	Transfusion Therapy		13764
									ac	Hemostatic Agents		13768
									ad	Pharmacologic Agents		13772
									D		Transfusion Therapy in Solid Organ Transplantation	13776
									1	Organ Procurement and Transplants		13780
									2	Immunologic Barriers – ABO and HLA		13784
									a	Management Across Immunologic Barriers		13788
									b	Organ Selection		13792
									c	Plasma Exchange		13796
									d	Pharmacologic Agents		13800
									3	Immunohematology		13804
									a	Patient Alloantibodies		13808
									b	Passenger Lymphocyte Antibodies		13812
									4	Transfusion Therapy		13816
									a	Liver		13820
									b	Heart		13824
									c	Lung		13828
									d	Kidney		13832
									e	Pancreas		13836
									f	Other		13840
									5	Special Needs		13844
									a	CMV Low Risk		13848
									b	Leukocyte Reduction		13852
									c	Irradiation		13856
									11		Biovigilance	13900
									A	Biovigilance/Hemovigilance		13904
									1	Requirements for Effective Program		13908
									2	Scope		13912
									a	What Should Be Reported		13916
										i	Adverse Reactions	13920
										ii	Adverse Incidents	13924

					iii	Near Misses				13928		
					b	Biovigilance				13932		
						i	Passive Reporting Versus Active Surveillance			13936		
						ii	Traceability			13940		
					c	Blood Donors				13944		
					d	Transfusion Recipients				13948		
				B	Immunomodulatory and Proinflammatory Effects of Allogeneic Blood Transfusion							13952
					1	Concepts and Overview				13956		
					2	Laboratory Features				13960		
					3	Beneficial Clinical Effects				13964		
						a	Enhanced Survival of Renal Allografts			13968		
						b	Reduced Risk of Recurrent Spontaneous Abortions			13972		
						c	Reduced Risk of recurrence of Crohn's Disease			13976		
					4	Deleterious Clinical Effects				13980		
						a	Increased Recurrence of Resected Malignancies			13984		
						b	Increased Risk of Postoperative Bacterial Infection			13988		
						c	Increased Risk of Short-Term Mortality			13992		
12 Platelets and Platelets Components										14000		
				A	Platelet Production (Thrombopoiesis)						14004	
					1	Megakaryocyte Development, Maturation, and Differentiation					14008	
					2	Thrombopoietic/Megakaryocyte/Hematopoietic Growth Factors					14012	
					3	Genetic and Cellular Regulation of Thrombopoiesis					14016	
					4	Platelet Production/Shedding/Release					14020	
				B	Platelet immunology						14024	
					1	Platelet Antigens (ABO, HLA, Platelet Specific)					14028	
					2	Disorders of Platelet Alloimmunization					14032	
					3	Platelet Autoimmunity					14036	
				C	Platelets in the Bloodstream						14040	
					1	Platelet Circulation/Distribution/Destruction					14044	
					2	Platelet Survival/Kinetics in Health and Disease					14048	
				D	Platelets and Hemostasis						14052	
					1	Normal Platelet Plug and Clot Formation					14056	
					2	Genetic/Congenital Platelet Disorders					14060	
					3	Acquired Platelet Disorders					14064	
				E	Platelet Transfusions						14068	
					1	Collection and Storage of Platelet Preparations/Concentrates					14072	
					2	Clinical Platelet Transfusions (Indications, Dose and Schedule)					14076	
					3	Alternatives to Platelet Transfusions (Thrombopoietic and Pharmacologic agents)					14080	
13 Obstetric and Pediatric Patients										14300		
				A	Obstetric Transfusion Practices						14304	
					1	Maternal Hematologic Disorders During Pregnancy					14308	

			2	Maternal Hemorrhage and Transfusions During Pregnancy	14312
			3	Fetal (Intrauterine) Transfusions	14316
		B	Hemolytic Disease of the Fetus and Newborn		14320
			1	ABO Incompatibility	14324
			2	Rh(D) and Other Fetal-Maternal RBC Incompatibilities	14328
			3	Fetal RBC Membrane/Metabolic or Hemoglobin Abnormalities	14332
			4	Management	14336
			a	Diagnostic and Surveillance Tests	14340
			b	Fetal and Neonatal Transfusions, Phototherapy, IVIG, etc)	14344
		C	Congenital Disorders of Clotting and Anticoagulant Proteins		14348
			1	Developmental Physiology of Plasma Proteins	14352
			2	Hemophilia A, B and von Willebrand Disease (Pathophysiology and Treatment)	14356
			a	DDAVP	13634
			3	Congenital Disorders of Non-Hemophilia Clotting Proteins	14360
			4	Congenital Disorders of Anticoagulant/Prothrombotic Proteins	14364
		D	Congenital Hemoglobinopathies and Hemolytic Anemias		14368
			1	Sickle Cell Disease (Pathophysiology and Treatment)	14372
			2	Non-Sickle Cell Hemoglobinopathies	14376
			3	Thalassemias (Pathophysiology and Treatment)	14380
			4	Congenital Red Cell Membrane and Enzyme Defects	14382
		E	Neonatal Transfusions		14384
			1	Anemia of Prematurity (Pathophysiology and Treatment)	14388
			2	Thrombocytopenia of Prematurity (Pathophysiology and Treatment)	14392
			3	Neonatal Blood Banking Practices (Dedicated Units, WBC-Reduction, Irradiation, etc)	14396
			4	Neonatal/Infant Plasma, Cryoprecipitate and Neutrophil Transfusions	14400
		F	Congenital Disorders of Hematopoiesis		14404
14			Hematopoietic Progenitor Cell (HPC) Transplantation		14500
		A	Biology of Marrow Transplantation – Indications, Methods, Results, Adverse Effects		14504
			1	Autologous	14508
			2	Allogeneic / Syngeneic	14512
		B	Biology of HPC and HPC Transplantation		14516
			1	HPC Biology	14520
			2	Identification and Measurement of HPC	14524
			3	Allogeneic/Syngeneic Donor Selection, Qualification, Eligibility	14528
			4	HLA Typing for HPC Transplantation	14532
			5	Processing Requirements for HPC	14536
			a	General	14540
			b	Patient-Specific	14544
			6	Regulatory, Compliance, Accreditation	14548
		C	HPC Sources and Collection		14552

			1	HPC - Marrow					14556
				a	Methods of Harvesting				14560
				b	Characteristics,				14564
				c	Adverse Effects				14568
			2	HPC – Apheresis – Characteristics and Adverse effects					14572
				a	Biology of Stem Cell Mobilization				14576
				b	Mobilization Regimens (Indications, Dose, Schedule, Efficacy, Adverse Effects)				14580
					i	Chemotherapy			14584
					ii	Growth Factors – G-CSF, GM-CSF			14588
					iii	Adhesion blockers – Plerixafor			14592
				c	Scheduling Mobilization and Apheresis Collection				14596
				d	Monitoring Mobilization and HPC Collection				14600
				e	Collection of Lymphocytes for Infusion (Donor Lymphocyte Infusion; DLI)				14604
				f	Apheresis Considerations – Techniques, Vascular Access, Donor Management, and Adverse Effects (Allogeneic vs				14608
			3	HPC - Cord Blood - Characteristics, and Methods					14612
				a	Cord Blood Banking - Donor Eligibility, Collection Methods, Processing, Testing, Cryopreservation				14616
				b	Cord Blood Unit Characteristics				14620
				c	Donor Selection for Transplant (Unrelated and Related)				14624
			4	Selection of the Appropriate HPC Source for a Given Patient					14628
		D	HPC Processing - Goals, Guidelines, and Methods (preparation for infusion)						14632
			1	HPC for Autologous Transplants					14636
			2	HPC for Allogeneic Transplant – Indications for Plasma, RBC Reduction,					14640
			3	Preparation of Cells for Donor Lymphocyte Infusion (DLI)					14644
			4	Cord Blood					14648
			5	Processing of Other CT Products (eg Antigen-Directed T cells, Marrow Stromal Cells)					14652
		E	HPC Storage and Preservation						14656
			1	Liquid Storage and Transport - Anticoagulant, Time, Temperature, Preservative, Cell Concentration					14660
			2	Rationale for Cryopreservation					14664
			3	Cryopreservation Theory and Practice					14668
				a	Cryoprotectants				14672
				b	Cryopreservaton Techniques – Controlled Rate, "Dump Freeze"				14676
				c	Storage - Mechanical and Liquid Nitrogen (Vapor vs Liquid),				14680
		F	Management of RBC Antigen Incompatibility in Allogeneic Transplantation - ABO/Rh, HLA, Other						14684
			1	Graft Management - Depletion of RBC (Major), Plasma (Minor)					14688
			2	Patient Transfusion Management					14692

				a	Major or Minor ABO Incompatibility – Immediate vs Delayed Hemolysis	14696
				b	Passenger Lymphocyte Syndrome (PLS), Cause, Diagnosis, Course, Therapy, Prevention	14700
			3		Ablative vs Non-Ablative (Immunosuppressive) Conditioning	14704
			4		Pediatric Considerations for Graft Manipulation	14708
		G			HPC Assessment - Pre- and Post-Processing and Post-Thaw	14712
			1		Cell Counts and Methods	14716
			2		HPC Measurement and Enumeration	14720
				a	Flow Cytometry CD34+ Cells and Other Markers (Single vs Dual platform)	14724
				b	Non-Flow Methods	14728
			3		HPC Viability Assessment Techniques	14732
			4		HPC Cell Culture Assays	14736
			5		HPC Functional and Differentiation Assays	14740
			6		HPC Microbial Assessment - Gram Stain, Cultures - Aerobic, Anaerobic, Fungal	14744
		H			Cell Selection Methods and Applications	14748
			1		Positive and Negative Selection - Techniques, Results, Indications	14752
			2		CD34 Cells and Others (eg Treg)	14756
			3		Tumor Purging and T Cell Depletion	14760
		I			HPC and CTP Thawing and Post-Thaw Processing (Apheresis, Marrow, Cord Blood, etc)	14764
			1		Direct HPC Infusion vs Pre-Infusion Cell Washing	14768
			2		Special Considerations for Preparation of Cord Blood HPC for infusion	14772
		J			HPC and CTP infusion	14776
			1		General Guidelines – Filters, No Irradiation, Infusion Rate, DMSO Limits, Infusion Pumps	14780
			2		Adverse Effects and Infusion Reactions – Incidence, Causes, Diagnosis, Management	14784
			3		Management and Infusion of Contaminated Products	14788
		K			Engraftment	14792
			1		Definition, Chimerism, Relationship to CD34+ Cell Doses	14796
			2		Rates - Autologous vs Allogeneic, Related vs MUD, HPC Source, Conditioning	14800
			3		Engraftment failure – Causes, Management	14804
			4		Immune Reconstitution Post-Transplant	14808
			5		Donor Lymphocyte Infusion – Rationale, Efficacy	14812
		L			HPC Lab quality assurance and accreditation - AABB, FACT, CAP, NMDP	14816
			1		Regulatory Considerations – Federal GMP, GTP; State	14820
		M			Laboratory Administration - Staff Hiring and Training, Facilities, Equipment, Supplies, Laboratory Development, Deviations, Non-Conforming HPC and	14824
		N			Experimental Cell Therapies	14828
			1		Institutional vs Commercially Sponsored	14832
			2		Types (eg Marrow Stromal, Adoptive Therapy with T Cells, Gene-Modified Cells)	14836

			3	Special Requirements for Processing (Clean Room, etc)	14840
			4	Regulatory Considerations	14844